Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as vital components of precision medicine, have demonstrated tremendous potential in the field of gene therapy.

Bicycle Therapeutics reveals new data on its Zelenectide Pevedotin initiative and plans to enhance development based on NECTIN4 gene amplification.

Among the many immune checkpoint inhibitors, Durvalumab (brand name Imfinzi) stands out as particularly noteworthy.

Candel Therapeutics reports that CAN-2409 met its main goal in a Phase 3 trial for prostate cancer, demonstrating a notable increase in disease-free survival.

Astria Therapeutics reports successful final outcomes from the target enrollment of the ALPHA-STAR Phase 1b/2 trial of Navenibart for HAE.

Arrowhead Pharmaceuticals shares preliminary clinical findings on ARO-CFB for treating complement-mediated conditions.

In the OlympiA Phase III trial, LYNPARZA® (olaparib) showed a significant increase in survival for early breast cancer patients.

Caliway reports positive outcomes from CBL-0204, a Phase 2b trial of CBL-514 aimed at decreasing abdominal subcutaneous fat, achieving all key efficacy goals.

Accent Therapeutics has initiated dosing for the first patient in its Phase 1/2 trial of ATX-559, alongside a change in its Chief Scientific Officer.

Anaptys reveals that the Phase 2b trial for ANB032, a BTLA agonist, failed to achieve its main and secondary objectives in treating atopic dermatitis.

Leriglitazone achieved its main goal in the NEXUS trial, which is crucial for children with cerebral Adrenoleukodystrophy.

Zealand Pharma reports enrollment of the first participant in the Phase 2b ZUPREME-1 study of petrelintide for individuals with overweight or obesity.